

# Micheline Piquette-Miller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4238061/publications.pdf>

Version: 2024-02-01

124  
papers

5,264  
citations

57758

44  
h-index

91884

69  
g-index

125  
all docs

125  
docs citations

125  
times ranked

5741  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics in pregnancy. , 2022, , 33-46.		1
2	Regulation of Drug Transport Proteins From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 461-484.	4.7	26
3	Impact of Inflammation and Infection on the Expression of Amino Acid Transporters in the Placenta: A Minireview. Drug Metabolism and Disposition, 2022, 50, 1251-1258.	3.3	5
4	Downregulation of BCRP (ABCG2) in Placenta of Rat Model of Preeclampsia. FASEB Journal, 2022, 36, .	0.5	0
5	Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta. Pharmaceutics, 2022, 14, 1376.	4.5	9
6	Drug Transporters: Efflux. , 2021, , .		0
7	Impact of Th-17 Cytokines on the Regulation of Transporters in Human Placental Explants. Pharmaceutics, 2021, 13, 881.	4.5	6
8	Viral model of maternal immune activation alters placental AMPK and mTORC1 signaling in rats. Placenta, 2021, 112, 36-44.	1.5	7
9	Pharmacists as Personalized Medicine Experts (PRIME): Experiences Implementing Pharmacist-Led Pharmacogenomic Testing in Primary Care Practices. Pharmacy (Basel, Switzerland), 2021, 9, 201.	1.6	8
10	Role of Elevated SFLT4 on the Regulation of Placental Transporters in Women With Preeclampsia. Clinical and Translational Science, 2020, 13, 580-588.	3.1	11
11	Essential role of STAT-3 dependent NF- $\kappa$ B activation on IL-6-mediated downregulation of hepatic transporters. European Journal of Pharmaceutical Sciences, 2020, 143, 105151.	4.0	8
12	Role of HIV and Antiretroviral Therapy on the Expression of Placental Transporters in Women with HIV. AAPS Journal, 2020, 22, 138.	4.4	9
13	SLC Neurotransmitter Transporters as Therapeutic Targets for Alcohol Use Disorder: A Narrative Review. Alcoholism: Clinical and Experimental Research, 2020, 44, 1965-1976.	2.4	6
14	Potential Limitations of Bioluminescent Xenograft Mouse Models: A Systematic Review. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 177-199.	2.1	6
15	Dysregulation of renal transporters in a rodent model of viral Infection. International Immunopharmacology, 2020, 80, 106135.	3.8	3
16	A Continuing Professional Development Program for Pharmacists Implementing Pharmacogenomics into Practice. Pharmacy (Basel, Switzerland), 2020, 8, 55.	1.6	26
17	The Age of Omics-Driven Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 477-481.	4.7	7
18	Dysregulation of solute carrier transporters in malaria-infected pregnant mice. Parasite Immunology, 2019, 41, e12614.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2498.	4.1	2
20	Poly(l:C) alters placental and fetal brain amino acid transport in a rat model of maternal immune activation. <i>American Journal of Reproductive Immunology</i> , 2019, 81, e13115.	1.2	23
21	Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats. <i>Pharmaceutics</i> , 2019, 11, 624.	4.5	11
22	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	4.7	110
23	Response to Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives™. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 604-604.	2.4	1
24	Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 472-485.	4.6	24
25	Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 854-867.	4.7	65
26	Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer. <i>Neuroscience</i> , 2018, 369, 51-65.	2.3	51
27	Battling the HIV/AIDS Epidemic: Triumphs and Barriers. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1042-1046.	4.7	2
28	STAT3 is involved in IL-6-Mediated Downregulation of Hepatic Transporters in Mice. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 325s-334s.	2.1	9
29	User considerations in assessing pharmacogenomic tests and their clinical support tools. <i>Npj Genomic Medicine</i> , 2018, 3, 26.	3.8	38
30	BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines. <i>Molecular Pharmaceutics</i> , 2018, 15, 2742-2753.	4.6	12
31	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 900-915.	4.7	91
32	Endotoxin Modulates the Expression of Renal Drug Transporters in HIV-1 Transgenic Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 117s-129s.	2.1	7
33	PREGNANCY OUTCOMES AFTER EXPOSURE TO TNF- $\alpha$ INHIBITORS FOR THE TREATMENT OF ARTHRITIC DISEASES: A META-ANALYSIS OF OBSERVATIONAL STUDIES. <i>Canadian Journal of Clinical Pharmacology</i> , 2018, 25, e53-e56.	1.1	6
34	Aprepitant and fosaprepitant drug interactions: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2148-2162.	2.4	62
35	Within Our Skin. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 8-12.	4.7	0
36	Impact of endotoxin on the expression of drug transporters in the placenta of HIV-1 transgenic (HIV-Tg) rats. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 94-102.	4.0	8

#	ARTICLE	IF	CITATIONS
37	Involvement of Nuclear Factor $\kappa$ B, not Pregnane X Receptor, in Inflammation-Mediated Regulation of Hepatic Transporters. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1077-1083.	3.3	20
38	Pharmacokinetics in Pregnancy. , 2017, , 39-49.		0
39	The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice. <i>Pharmaceutics</i> , 2017, 9, 49.	4.5	4
40	The Bugs Within Our Body: The Human Microbiota. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 570-574.	4.7	2
41	Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats. <i>Drug Metabolism and Disposition</i> , 2016, 44, 709-719.	3.3	9
42	Effect of a high-fat diet on the hepatic expression of nuclear receptors and their target genes: relevance to drug disposition. <i>British Journal of Nutrition</i> , 2015, 113, 507-516.	2.3	34
43	Maternal bacterial infections impact expression of drug transporters in human placenta. <i>International Immunopharmacology</i> , 2015, 26, 349-356.	3.8	38
44	Blood-brain barrier: An impediment to neuropharmaceuticals. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 308-313.	4.7	32
45	Polyinosinic/Polycytidylic Acid-Mediated Changes in Maternal and Fetal Disposition of Lopinavir in Rats. <i>Drug Metabolism and Disposition</i> , 2015, 43, 951-957.	3.3	12
46	Malaria Infection Alters the Expression of Hepatobiliary and Placental Drug Transporters in Pregnant Mice. <i>Drug Metabolism and Disposition</i> , 2014, 42, 603-610.	3.3	19
47	The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. <i>Psychopharmacology</i> , 2014, 231, 841-852.	3.1	35
48	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. <i>Molecular Pharmaceutics</i> , 2014, 11, 1301-1313.	4.6	9
49	Inflammation: The Dynamic Force of Health and Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 401-405.	4.7	8
50	Network Medicine: Finding the Links to Personalized Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 613-616.	4.7	10
51	Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2013, 10, 3315-3322.	4.6	8
52	Recent advances in drug delivery strategies for treatment of ovarian cancer. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 567-583.	5.0	39
53	Epigenetics: A New Link Toward Understanding Human Disease and Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 669-673.	4.7	11
54	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 69-89.	3.1	89

#	ARTICLE	IF	CITATIONS
55	Expression of ABC Efflux Transporters in Placenta from Women with Insulin-Managed Diabetes. PLoS ONE, 2012, 7, e35027.	2.5	41
56	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. Journal of Controlled Release, 2012, 158, 379-385.	9.9	29
57	Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer. Molecular Pharmaceutics, 2011, 8, 260-269.	4.6	46
58	Optimizing Cancer Care: Is the Future Bright?. Clinical Pharmacology and Therapeutics, 2011, 90, 347-350.	4.7	5
59	Docetaxel Distribution Following Intraperitoneal Administration in Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 90.	2.1	12
60	Gestational and Pregnane X Receptor-Mediated Regulation of Placental ATP-Binding Cassette Drug Transporters in Mice. Drug Metabolism and Disposition, 2011, 39, 465-471.	3.3	18
61	Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes. Drug Metabolism and Disposition, 2011, 39, 1850-1859.	3.3	14
62	Pharmacokinetics in pregnancy. , 2011, , 39-45.		4
63	Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer. Molecular Cancer Therapeutics, 2011, 10, 1289-1299.	4.1	68
64	Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 1820-1830.	4.1	36
65	Impact of Hyperlipidemia on Plasma Protein Binding and Hepatic Drug Transporter and Metabolic Enzyme Regulation in a Rat Model of Gestational Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 21-32.	2.5	25
66	Breast Cancer Resistance Protein (BCRP)-Mediated Glyburide Transport: Effect of the C421A/Q141K BCRP Single-Nucleotide Polymorphism. Drug Metabolism and Disposition, 2010, 38, 740-744.	3.3	51
67	Impact of Polyinosinic/Polycytidylic Acid on Placental and Hepatobiliary Drug Transporters in Pregnant Rats. Drug Metabolism and Disposition, 2010, 38, 1760-1766.	3.3	64
68	Polymeric drug delivery systems for localized cancer chemotherapy. Drug Delivery, 2010, 17, 365-375.	5.7	158
69	Impact of Acute Streptozotocin-Induced Diabetes on ABC Transporter Expression in Rats. Chemistry and Biodiversity, 2009, 6, 1943-1959.	2.1	22
70	Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. International Journal of Pharmaceutics, 2009, 377, 76-84.	5.2	32
71	Pharmacogenetics of Pharmacoeology: Which Route to Personalized Medicine?. Clinical Pharmacology and Therapeutics, 2009, 85, 343-348.	4.7	8
72	Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials, 2009, 30, 3818-3824.	11.4	82

#	ARTICLE	IF	CITATIONS
73	Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 243-257.	3.3	106
74	Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend. <i>International Journal of Pharmaceutics</i> , 2008, 360, 83-90.	5.2	19
75	Translational Pharmacology: Harnessing Increased Specialization of Research Within the Basic Biological Sciences. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 797-801.	4.7	8
76	Pharmacokinetic Studies in Pregnant Women. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 184-187.	4.7	43
77	Regulation of Transporters by Nuclear Hormone Receptors: Implications during Inflammation. <i>Molecular Pharmaceutics</i> , 2008, 5, 67-76.	4.6	57
78	Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 149-157.	4.3	63
79	Effect of Endotoxin on the Expression of Placental Drug Transporters and Glyburide Disposition in Pregnant Rats. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1944-1950.	3.3	53
80	Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 630-637.	4.1	61
81	Animal Models of Acute Moderate Hypoxia Are Associated with a Down-Regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and Up-Regulation of CYP3A6 and P-glycoprotein in Liver. <i>Drug Metabolism and Disposition</i> , 2007, 35, 765-771.	3.3	79
82	KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 679-685.	2.1	12
83	The Art and Science of Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 311-315.	4.7	79
84	Drug transport across the placenta, role of the ABC drug efflux transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 819-830.	3.3	62
85	Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. <i>British Journal of Pharmacology</i> , 2007, 151, 367-376.	5.4	109
86	Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. <i>Journal of Controlled Release</i> , 2007, 117, 20-27.	9.9	57
87	Novel drug-delivery strategies for the treatment of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 587-593.	0.4	0
88	Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 907-914.	2.3	63
89	REGULATION OF DRUG TRANSPORTERS: DURING INFECTION AND INFLAMMATION. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2007, 7, 99-111.	3.4	146
90	Synthesis and Physicochemical and Dynamic Mechanical Properties of a Water-Soluble Chitosan Derivative as a Biomaterial. <i>Biomacromolecules</i> , 2006, 7, 2845-2855.	5.4	121

#	ARTICLE	IF	CITATIONS
91	Synthesis and Physicochemical and Dynamic Mechanical Properties of a Water-Soluble Chitosan Derivative as a Biomaterial. <i>Biomacromolecules</i> , 2006, 7, 3548-3548.	5.4	13
92	In vivo disposition and stability of DNA frayed wires in mice. <i>International Journal of Biological Macromolecules</i> , 2006, 39, 310-316.	7.5	0
93	<sup>99m</sup> Tc-Sestamibi, A Sensitive Probe for In Vivo Imaging of P-Glycoprotein Inhibition by Modulators and <i>mdr1</i> Antisense Oligodeoxynucleotides. <i>Molecular Imaging and Biology</i> , 2006, 8, 333-339.	2.6	12
94	Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 61-69.	2.3	23
95	In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. <i>International Journal of Cancer</i> , 2006, 119, 414-422.	5.1	67
96	Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines. <i>Current Cancer Drug Targets</i> , 2006, 6, 295-311.	1.6	79
97	THE ROLE OF PREGNANE X RECEPTOR IN 2-ACETYLAMINOFUORENE-MEDIATED INDUCTION OF DRUG TRANSPORT AND -METABOLIZING ENZYMES IN MICE. <i>Drug Metabolism and Disposition</i> , 2006, 34, 405-409.	3.3	47
98	p53 and Multidrug Resistance Transporters in the Central Nervous System. , 2006, , 373-388.		0
99	In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. <i>Journal of Controlled Release</i> , 2005, 104, 181-191.	9.9	63
100	IMPACT OF ENDOTOXIN-INDUCED CHANGES IN P-GLYCOPROTEIN EXPRESSION ON DISPOSITION OF DOXORUBICIN IN MICE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 820-828.	3.3	73
101	The Involvement of the Pregnane X Receptor in Hepatic Gene Regulation during Inflammation in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 841-848.	2.5	159
102	Detection of P-glycoprotein activity in endotoxemic rats by <sup>99m</sup> Tc-sestamibi imaging. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1537-45.	5.0	49
103	Functional comparison of single- and double-stranded <i>mdr1</i> antisense oligodeoxynucleotides in human ovarian cancer cell lines. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 516-27.	2.1	9
104	Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. <i>Journal of Neurochemistry</i> , 2004, 89, 788-800.	3.9	97
105	Cytokines Alter the Expression and Activity of the Multidrug Resistance Transporters in Human Hepatoma Cell Lines; Analysis Using RT-PCR and cDNA Microarrays. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 2152-2163.	3.3	61
106	Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. <i>Toxicology</i> , 2003, 184, 211-226.	4.2	34
107	Downregulation of <i>mdr1a</i> expression in the brain and liver during CNS inflammation alters the <i>in vivo</i> disposition of digoxin. <i>British Journal of Pharmacology</i> , 2003, 139, 35-48.	5.4	111
108	INDUCTION OF ABCC3 (MRP3) BY PREGNANE X RECEPTOR ACTIVATORS. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1296-1299.	3.3	136



#	ARTICLE	IF	CITATIONS
109	Inflammatory Cytokines, but Not Bile Acids, Regulate Expression of Murine Hepatic Anion Transporters in Endotoxemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 273-281.	2.5	197
110	Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2001, 79, 876-884.	1.4	74
111	Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. <i>International Immunopharmacology</i> , 2001, 1, 189-199.	3.8	132
112	Decreased expression of P-glycoprotein in interleukin-1 $\beta$ and interleukin-6 treated rat hepatocytes. <i>Inflammation Research</i> , 2001, 50, 362-370.	4.0	85
113	Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1786-1792.	2.1	38
114	Endotoxin Downregulates Hepatic Expression of P-Glycoprotein and MRP2 in 2-Acetylaminofluorene-Treated Rats. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , 2000, 4, 90-97.	1.6	41
115	Inflammation and Interleukin-6 Mediate Reductions in the Hepatic Expression and Transcription of the mdr1a and mdr1b Genes. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , 2000, 4, 248-256.	1.6	63
116	Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. <i>Pharmaceutical Research</i> , 1998, 15, 706-711.	3.5	121
117	Expression of Human Polyspecific Renal Organic Cation Transport Activity in <i>Xenopus laevis</i> Oocytes. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 753-755.	3.3	3
118	Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. <i>Pharmaceutical Research</i> , 1997, 14, 1524-1532.	3.5	82
119	Characterization of guanidine transport in human renal brush border membranes. <i>Pharmaceutical Research</i> , 1997, 14, 936-941.	3.5	16
120	PHARMACOKINETICS AND MULTIPLE PEAKING OF ACEBUTOLOL ENANTIOMERS IN RATS. , 1997, 18, 543-556.		29
121	PHARMACOKINETICS AND MULTIPLE PEAKING OF ACEBUTOLOL ENANTIOMERS IN RATS. <i>Biopharmaceutics and Drug Disposition</i> , 1997, 18, 543-556.	1.9	2
122	Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. <i>Pharmaceutical Research</i> , 1993, 10, 294-299.	3.5	61
123	Effect of Aging on the Pharmacokinetics of Acebutolol Enantiomers. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 148-156.	2.0	17
124	Pharmacokinetics of Acebutolol Enantiomers in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 313-316.	3.3	27